PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Real-world lecanemab in Chinese patients: low ARIA, financial-driven discontinuation

lecanemabanti-amyloid monoclonal antibodyAlzheimer's diseaseARIAblood-based biomarkersApoEreal-world studyobservational cohortChinaneuropharmacology Neurology / Neuropharmacology

Background Information

Lecanemab shows safety but no cognitive boost in real-world AD study.

Lecanemab's safety and effectiveness in Alzheimer's disease (AD) need assessment in diverse populations. In 1,042 patients, amyloid-related imaging abnormalities occurred in 7.87% and infusion-related reactions in 16.12%. No change in Clinical Dementia Rating Scale-Sum of Boxes was seen at 12 months. The study shows lecanemab has a favorable safety profile but no notable cognitive improvement, highlighting the need for more research with control groups. Lecanemab demonstrates safety but no cognitive improvement in this 12-month study.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Wu H, Chen Q, Fang M, Tang H, Liu H, Liu J, Zhang J, Chi L, Liu S, Xin J, Leng L, Wang P, Chi S, Li Y, Chen J, Zhang L, Zhang J, Ma Q, Wang X, Meng X, Nao J, Li X, Lv Y, Jia Y, Zhao Q, Liu C, Gan J, Zhu J, Song Y, Li H, Fei M, Guo X, Liu J, Peng G, Chen X, Ji Y

Citation: Wu H, Chen Q, Fang M, et al. Lecanemab use in Chinese patients with Alzheimer's disease: a 12-month multicenter real-world study. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2026;22(8):e71702. doi:10.1002/alz.71702

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.